Cargando…
Increased Time in Range with Ultra Rapid Lispro Treatment in Participants with Type 2 Diabetes: PRONTO-Time in Range
INTRODUCTION: To evaluate time in range metrics and HbA1c in people with type 2 diabetes (T2D) treated with ultra rapid lispro (URLi) using continuous glucose monitoring (CGM) for the first time in this population. METHODS: This was a Phase 3b, 12-week, single-treatment study in adults with T2D on b...
Autores principales: | Bailey, Timothy S., Bode, Bruce W., Wang, Qianqian, Knights, Alastair W., Chang, Annette M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10081815/ https://www.ncbi.nlm.nih.gov/pubmed/37029268 http://dx.doi.org/10.1007/s13300-023-01400-w |
Ejemplares similares
-
Assessing Time in Range with Postprandial Glucose-Focused Titration of Ultra Rapid Lispro (URLi) in People with Type 1 Diabetes
por: Bergenstal, Richard M., et al.
Publicado: (2023) -
Ultra-Rapid Lispro Improves Postprandial Glucose Control and Time in Range in Type 1 Diabetes Compared to Lispro: PRONTO-T1D Continuous Glucose Monitoring Substudy
por: Malecki, Maciej T., et al.
Publicado: (2020) -
Efficacy and safety of ultra‐rapid lispro versus lispro in children and adolescents with type 1 diabetes: The PRONTO‐Peds trial
por: Wadwa, R. Paul, et al.
Publicado: (2022) -
Improved postprandial glucose control with ultra rapid lispro versus lispro with continuous subcutaneous insulin infusion in type 1 diabetes: PRONTO‐Pump‐2
por: Warren, Mark, et al.
Publicado: (2021) -
Efficacy and Safety of Ultra-Rapid Lispro Versus Lispro in Patients with Type 1 and 2 Diabetes: Indian Subpopulation Analyses of the PRONTO-T1D and PRONTO-T2D Trials
por: Bhattacharyya, Arpandev, et al.
Publicado: (2022)